Compare ClearPoint Neuro Inc (CLPT) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Nutanix Inc — how do they compare? ClearPoint Neuro Inc trades at $16.07 (market cap $478.63M), while Nutanix Inc trades at $55.65 (market cap $14.99B). The key difference: Nutanix Inc is far larger — about 31.3× ClearPoint Neuro Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | NTNX | |
|---|---|---|
Market Cap | $478.63M | $14.99B |
Sector | Health | Technology |
52-Week High | $29.60 | $81.12 |
52-Week Low | $8.66 | $34.41 |
Enterprise Value | $506.63M | $14.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Nutanix (NTNX) trades at $55.22, up 0.78% on the day, reflecting positive momentum. The stock exhibits a bullish technical trend with strong moving average support and is trading near key resistance at $56. Fundamentally, the company demonstrates robust revenue growth, with Q3 2026 results beating expectations, and maintains a high gross profit margin of 87.09%. Recent news highlights strategic partnerships and NVIDIA certification for its AI infrastructure solutions.
The outlook for NTNX is positive, driven by consistent earnings beats, strong analyst consensus (62.5% Buy ratings), and a $57.80 price target suggesting modest upside. Key risks include its high valuation multiples (P/E of 58.39) and execution challenges in a competitive cloud software market. Investor sentiment is buoyed by its positioning in hybrid multicloud and AI growth areas.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
